Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/91494
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer |
Author: | Voskoboynik, M. Staffurth, J. Malik, Z. Sweeney, C. Chowdhury, S. |
Citation: | Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care, 2014; 14(11):1253-1256 |
Publisher: | Expert Reviews |
Issue Date: | 2014 |
ISSN: | 1473-7140 1744-8328 |
Statement of Responsibility: | Mark Voskoboynik, John Staffurth, Zafar Malik, Christopher Sweeney and Simon Chowdhury |
Abstract: | Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer. |
Keywords: | CHAARTED; docetaxel; hormone sensitive; metastatic prostate cancer; Sweeney |
Description: | Editorial |
Rights: | © 2014 Informa UK Ltd. |
DOI: | 10.1586/14737140.2014.971112 |
Published version: | http://dx.doi.org/10.1586/14737140.2014.971112 |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.